Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • The Effect of Perioperative Intravenous Lidocaine Infusion on Post-amputation Pain in Amputee Patients

    NCT07783867 · start 2026-10-01

    Registered record
    Registry ID
    NCT07783867
    Conditions
    Amputation
    Interventions
    Lidocaine Hydrochloride, Injectable; 0.9% normal saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-12-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmputation
    InterventionLidocaine Hydrochloride, Injectable; 0.9% normal saline
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer

    NCT07793578 · start 2026-10-01

    Registered record
    Registry ID
    NCT07793578
    Conditions
    Advanced Urothelial Carcinoma
    Interventions
    capivasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2030-09-30
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Urothelial Carcinoma
    Interventioncapivasertib
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Clinical, Dermoscopic, and Mycological Evaluations of Resistant Dermatophytosis

    NCT07796854 · start 2026-10-01

    Registered record
    Registry ID
    NCT07796854
    Conditions
    Fungal Skin Infection; Tinea Corporis
    Interventions
    Direct microscopic KOH examination; Culture:; Antifungal susceptibility testing:; Conventional PCR:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2027-08-20
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Skin Infection; Tinea Corporis
    InterventionDirect microscopic KOH examination; Culture:; Antifungal susceptibility testing:; Conventional PCR:
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Brain and Blood Vessel Health Following Endometriosis Treatment in People With Endometriosis

    NCT07799246 · start 2026-10-01

    Registered record
    Registry ID
    NCT07799246
    Conditions
    Endometriosis; Endometriosis and Dysmenorrhea; Endometriosis (Diagnosis)
    Interventions
    Investigate how norethindrone acetate, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health; Investigate how Orlissa, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health; Investigate how Oriahnn, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis; Endometriosis and Dysmenorrhea; Endometriosis (Diagnosis)
    InterventionInvestigate how norethindrone acetate, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health; Investigate how Orlissa, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health; Investigate how Oriahnn, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health
    PhasePhase 4
    Registry statusNot yet recruiting

  • Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

    NCT07801248 · start 2026-10-01

    Registered record
    Registry ID
    NCT07801248
    Conditions
    Acute Skin Graft Versus Host Disease (GVHD)
    Interventions
    Ruxolitinib 1.5% cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Skin Graft Versus Host Disease (GVHD)
    InterventionRuxolitinib 1.5% cream
    PhasePhase 1
    Registry statusNot yet recruiting

  • Randomized Evaluation of Indocyanine Green Fluorescence Angiography-Guided Versus Standard Clinical Perfusion Assessment During Gluteal Permanent Synthetic Filler Removal

    NCT07808957 · start 2026-10-01

    Registered record
    Registry ID
    NCT07808957
    Conditions
    Soft Tissue Filler Complication; Surgical Flap Ischemia; Tissue Necrosis
    Interventions
    Indocyanine Green; Standard Clinical Perfusion Assessment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2027-10-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Filler Complication; Surgical Flap Ischemia; Tissue Necrosis
    InterventionIndocyanine Green; Standard Clinical Perfusion Assessment
    PhaseNot applicable
    Registry statusNot yet recruiting

  • The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

    NCT07810738 · start 2026-10-01

    Registered record
    Registry ID
    NCT07810738
    Conditions
    Late Life Treatment Resistant Depression; Depression - Major Depressive Disorder; Treatment Resistant Depression
    Interventions
    Aripiprazole Augmentation; Bupropion Augmentation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-09-15
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLate Life Treatment Resistant Depression; Depression - Major Depressive Disorder; Treatment Resistant Depression
    InterventionAripiprazole Augmentation; Bupropion Augmentation
    PhasePhase 2
    Registry statusNot yet recruiting

  • Exploratory Evaluation of the BiP Inhibitor BPR001-615 in Primary Cells and the Diagnostic Value of Circulating BiP in Colorectal Adenocarcinomas

    NCT07813884 · start 2026-10-01

    Registered record
    Registry ID
    NCT07813884
    Conditions
    Colorectal Adenocarcinoma
    Interventions
    BPR001-615
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-10-01
    Completion
    2027-10-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Adenocarcinoma
    InterventionBPR001-615
    PhaseNot applicable
    Registry statusRecruiting

  • Citrus Sinensis Peel Gel for Radiation-Induced Oral Mucositis

    NCT07813923 · start 2026-10-01

    Registered record
    Registry ID
    NCT07813923
    Conditions
    Radiation-induced Oral Mucositis; Head and Neck Cancer
    Interventions
    Citrus sinensis peel extract gel; Conventional supportive treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2027-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRadiation-induced Oral Mucositis; Head and Neck Cancer
    InterventionCitrus sinensis peel extract gel; Conventional supportive treatment
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Effects of Remimazolam on Postoperative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients Undergoing Aortic Arch Surgery

    NCT07816068 · start 2026-10-01

    Registered record
    Registry ID
    NCT07816068
    Conditions
    Aortic Aneurysm of the Proximal Arch; Aortic Aneurysms Arch; Aortic Arch Disease; Postoperative Delirium (POD); POSTOPERATIVE DELIRIUM AND POSTOPERATIVE COGNITIVE DECLINE; Postoperative Delirium
    Interventions
    Remimazolam Besylate; propofol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2027-11-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAortic Aneurysm of the Proximal Arch; Aortic Aneurysms Arch; Aortic Arch Disease; Postoperative Delirium (POD) +2 more
    InterventionRemimazolam Besylate; propofol
    PhasePhase 4
    Registry statusNot yet recruiting

  • Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence

    NCT07831187 · start 2026-10-01

    Registered record
    Registry ID
    NCT07831187
    Conditions
    Glioblastoma
    Interventions
    Entacapone; Bevacizumab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-09-30
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma
    InterventionEntacapone; Bevacizumab; Placebo
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders

    NCT05455996 · start 2026-10

    Registered record
    Registry ID
    NCT05455996
    Conditions
    Post-Traumatic Stress Disorder; Adjustment Disorders
    Interventions
    MDMA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2028-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Traumatic Stress Disorder; Adjustment Disorders
    InterventionMDMA
    PhasePhase 2
    Registry statusNot yet recruiting

  • Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients

    NCT06777511 · start 2026-10

    Registered record
    Registry ID
    NCT06777511
    Conditions
    Amputation; Osseointegration
    Interventions
    5-aminolevulinic acid (5-ALA); Photodynamic therapy (PDT)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2028-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmputation; Osseointegration
    Intervention5-aminolevulinic acid (5-ALA); Photodynamic therapy (PDT)
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments

    NCT06905834 · start 2026-10

    Registered record
    Registry ID
    NCT06905834
    Conditions
    Dry Eye Disease (DED); Graft-Versus-Host Disease(GVHD)
    Interventions
    Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2028-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease (DED); Graft-Versus-Host Disease(GVHD)
    InterventionSubconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC
    PhasePhase 2
    Registry statusNot yet recruiting

  • Vibegron for ENergy Thinking and Resilience in Aging

    NCT06987383 · start 2026-10

    Registered record
    Registry ID
    NCT06987383
    Conditions
    Obesity
    Interventions
    Vibegron; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2028-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionVibegron; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.